ArticleSurgical neurology international2026
Effect of erythropoietin on serum brain-derived neurotrophic factor after experimental traumatic brain injury in Wistar rats: A randomized controlled laboratory study.
Article in Surgical neurology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Traumatic brain injury (TBI) initiates secondary injury cascades that can reduce brain-derived neurotrophic factor (BDNF), a key mediator of synaptic plasticity and repair. Erythropoietin (EPO) has nonhematopoietic neuroprotective effects and may upregulate BDNF, while serum BDNF is a feasible translational pharmacodynamic biomarker. The aim of this study was to evaluate whether repeated intraperitoneal EPO administration increased serum BDNF levels on post-injury day 7 in Wistar rats with experimental TBI. Methods: Male Wistar rats (2.5-3 months; 200-250 g) were allocated to sham, TBI + normal saline, or TBI + EPO (5,000 IU/kg intraperitoneally at 1 h, 24 h, 48 h, and day 7). Focal unilateral TBI was induced using a weight-drop model under ketamine/xylazine anesthesia. Serum BDNF (ng/mL) was measured by enzyme-linked immunosorbent assay on day 7. Group differences were tested using one-way analysis of variance with Tukey Results: Analyzable samples were sham Conclusion: Repeated EPO dosing significantly increased serum BDNF 7 days after experimental TBI, supporting BDNF-linked neuroprotective signaling and the utility of serum BDNF as a pharmacodynamic biomarker. Dose- response, longer follow-up, and multimodal outcomes are required before clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.